Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Petros Pharmaceuticals, Inc. (PTPI)
USD0.00
0.00 (-20.00%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
1185 Avenue of the Americas 10036
New York City, NY, US
New York City, NY, US
CEO
Joshua N. Silverman
Website
petrospharma.com
IPO
2020-12-02
CIK 1815903 ISIN US71678J3086
Description
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Neurotrope | NTRP | 2020-07-23 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
0.00 (-20.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
101.4K
Beta
1.87
Float Shares
31.10M
Free Float %
99.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -14.29% | -14.29% | -14.29% | -50.00% | -25.00% | -82.86% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
18.30
+457,461.2%
DCF (Levered)
18.30
+457,467.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-38.32
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-100.0%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+53.3% ★ Q1'26: +99.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +153.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3,396.8% Q1'26: +3,878.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
5.82M
est: 7.70M (-24.4%)
|
5.11M
est: 5.43M (-5.9%)
|
—
est: 5.48M (-100.0%)
|
11.03M
11.03M – 11.03M
+101.4% YoY
|
20.63M
20.63M – 20.63M
+87.1% YoY
|
27.78M
27.78M – 27.78M
+34.7% YoY
|
| EBITDA |
-4.21M
est: -6.08M (+30.7%)
|
-10.81M
est: -2.12M (-411.3%)
|
-4.64M
est: -2.13M (-117.8%)
|
-4.29M
-4.29M – -4.29M
-101.4% YoY
|
-8.03M
-8.03M – -8.03M
-87.1% YoY
|
-10.81M
-10.81M – -10.81M
-34.7% YoY
|
| EBIT |
-7.63M
est: -7.70M (+1.0%)
|
-13.76M
est: -3.26M (-322.0%)
|
-4.64M
est: -3.29M (-41.3%)
|
-6.62M
-6.62M – -6.62M
-101.4% YoY
|
-12.38M
-12.38M – -12.38M
-87.1% YoY
|
-16.67M
-16.67M – -16.67M
-34.7% YoY
|
| Net Income |
-8.16M
est: -1.03B (+99.2%)
|
-14.32M
est: -14.94B (+99.9%)
|
1.91M
est: -7.65B (+100.0%)
|
-7.72B
-7.72B – -7.72B
-0.9% YoY
|
-4.91B
-4.91B – -4.91B
+36.4% YoY
|
95.42M
95.42M – 95.42M
+101.9% YoY
|
| SGA |
9.26M
est: 13.83M (-33.0%)
|
8.75M
est: 9.06M (-3.4%)
|
4.64M
est: 9.13M (-49.2%)
|
18.38M
18.38M – 18.38M
+101.4% YoY
|
34.39M
34.39M – 34.39M
+87.1% YoY
|
46.32M
46.32M – 46.32M
+34.7% YoY
|
| EPS |
-6.35
est: -128.75 (+95.1%)
|
-3.34
est: -53.25 (+93.7%)
|
-1.56
est: -27.25 (+94.3%)
|
-27.50
-27.50 – -27.50
-0.9% YoY
|
-17.50
-17.50 – -17.50
+36.4% YoY
|
0.34
0.34 – 0.34
+101.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-20 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-01 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.01M
OE per share TTM
-0.17
Owner's Yield
-2,167.16%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JCP III SM AIV, L.P. | 3.40M | 34.90% | — | 3.40M | — | 10.00 | PN | 6. Citizenship or Place of Organization | 2020-12-11 | ↗ |
| 2 | John D. Shulman | 3.40M | 34.90% | — | 3.40M | — | 10.00 | IN | 6. Citizenship or Place of Organization | 2020-12-11 | ↗ |
| 3 | Juggernaut Partners III GP, L.P. | 3.40M | 34.90% | — | 3.40M | — | 10.00 | PN | 6. Citizenship or Place of Organization | 2020-12-11 | ↗ |
| 4 | Daniel B. Asher | 1.60M | 7.20% | — | 1.60M | — | 1.60M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 5 | Intracoastal Capital LLC | 1.60M | 7.20% | — | 1.60M | — | 1.60M | OO | Delaware | 2022-02-11 | ↗ |
| 6 | Mitchell P. Kopin | 1.60M | 7.20% | — | 1.60M | — | 1.60M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 7 | Richard Abbe | 1.19M | 4.99% | 399.6K | 794.6K | 399.6K | 794.6K | HC, IN | United States of America | 2022-02-23 | ↗ |
| 8 | George W. Haywood | 1.02M | 7.60% | 1.02M | — | 1.02M | — | IN | United States | 2021-10-27 | ↗ |
| 9 | Iroquois Capital Management L.L.C. | 794.6K | 4.18% | — | 794.6K | — | 794.6K | OO | Delaware | 2022-02-23 | ↗ |
| 10 | Kimberly Page | 794.6K | 4.18% | — | 794.6K | — | 794.6K | IN | United States of America | 2022-02-23 | ↗ |
| 11 | Metuchen Therapeutics, LLC | 185.4K | 1.90% | — | 185.4K | — | 10.00 | OO | 6. Citizenship or Place of Organization | 2020-12-11 | ↗ |
| 12 | METP Holdings, LLC | 13.6K | 0.10% | — | 13.6K | — | 10.00 | OO | 6. Citizenship or Place of Organization | 2020-12-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
6.75M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+6,750,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | WALKER WAYNE REMELL | Director | A-Award | A | Common Stock | 500,000 | 0.00 | — | 506,333 | D | ↗ |
| 2026-01-02 | Silverman Joshua | Director | A-Award | A | Common Stock | 4,375,000 | 0.00 | — | 4,415,450 | D | ↗ |
| 2026-01-02 | Boctor Fady | Officer | A-Award | A | Common Stock | 500,000 | 0.00 | — | 519,986 | D | ↗ |
| 2026-01-02 | Bernstein Bruce | Director | A-Award | A | Common Stock | 1,875,000 | 0.00 | — | 1,887,334 | D | ↗ |
| 2025-02-19 | WALKER WAYNE REMELL | Director | A-Award | A | Common Stock | 150,000 | 0.00 | — | 158,314 | D | ↗ |
| 2025-02-19 | Silverman Joshua | Director | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,011,237 | D | ↗ |
| 2025-02-19 | Boctor Fady | Officer | A-Award | A | Common Stock | 450,000 | 0.00 | — | 499,645 | D | ↗ |
| 2025-02-19 | Bernstein Bruce | Director | A-Award | A | Common Stock | 300,000 | 0.00 | — | 308,346 | D | ↗ |
| 2025-02-19 | Arnold Mitchell | Officer | A-Award | A | Common Stock | 150,000 | 0.00 | — | 150,000 | D | ↗ |
| 2023-12-21 | WALKER WAYNE REMELL | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.41 | 56.4K | 40,000 | — | ↗ |
| 2023-12-21 | Silverman Joshua | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.41 | 56.4K | 40,000 | — | ↗ |
| 2023-12-21 | Bradley Greg | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.41 | 56.4K | 40,000 | — | ↗ |
| 2023-12-21 | Boctor Fady | Officer | A-Award | A | Common Stock | 49,645 | 0.00 | — | 49,645 | — | ↗ |
| 2023-12-21 | Bernstein Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.41 | 56.4K | 40,000 | — | ↗ |
| 2023-12-21 | Arnold Mitchell | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.41 | 28.2K | 20,000 | — | ↗ |
| 2023-04-26 | WALKER WAYNE REMELL | Director | M-Exempt | A | Common Stock | 6,050 | 0.00 | — | 8,314 | — | ↗ |
| 2023-04-26 | Silverman Joshua | Director | M-Exempt | D | Restricted Stock Units | 6,722 | 0.00 | — | 0 | — | ↗ |
| 2023-04-26 | Bradley Greg | Director | M-Exempt | D | Restricted Stock Units | 6,050 | 0.00 | — | 0 | — | ↗ |
| 2023-04-26 | Bernstein Bruce | Director | M-Exempt | D | Restricted Stock Units | 6,050 | 0.00 | — | 0 | — | ↗ |
| 2023-04-10 | WALKER WAYNE REMELL | Director | A-Award | A | Stock Option (Right to Buy) | 39,000 | 0.99 | 38.6K | 39,000 | — | ↗ |
| 2023-04-10 | Silverman Joshua | Director | A-Award | A | Stock Option (Right to Buy) | 39,000 | 0.99 | 38.6K | 39,000 | — | ↗ |
| 2023-04-10 | Bradley Greg | Director | A-Award | A | Stock Option (Right to Buy) | 39,000 | 0.99 | 38.6K | 39,000 | — | ↗ |
| 2023-04-10 | Bernstein Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 39,000 | 0.99 | 38.6K | 39,000 | — | ↗ |
| 2023-01-20 | WALKER WAYNE REMELL | Director | M-Exempt | D | Restricted Stock Units | 2,264 | 0.00 | — | 0 | — | ↗ |
| 2023-01-20 | Silverman Joshua | Director | M-Exempt | D | Restricted Stock Units | 2,515 | 0.00 | — | 0 | — | ↗ |
| 2023-01-20 | Bradley Greg | Director | M-Exempt | D | Restricted Stock Units | 2,264 | 0.00 | — | 0 | — | ↗ |
| 2023-01-20 | Bernstein Bruce | Director | M-Exempt | D | Restricted Stock Units | 2,264 | 0.00 | — | 0 | — | ↗ |
| 2022-04-07 | WALKER WAYNE REMELL | Director | A-Award | A | Restricted Stock Units | 60,505 | 0.00 | — | 60,505 | — | ↗ |
| 2022-04-07 | Silverman Joshua | Director | A-Award | A | Restricted Stock Units | 67,227 | 0.00 | — | 67,227 | — | ↗ |
| 2022-04-07 | Bradley Greg | Director | A-Award | A | Restricted Stock Units | 60,505 | 0.00 | — | 60,505 | — | ↗ |
| 2022-04-07 | Bernstein Bruce | Director | A-Award | A | Restricted Stock Units | 60,505 | 0.00 | — | 60,505 | — | ↗ |
| 2021-12-22 | WALKER WAYNE REMELL | Director | A-Award | A | Restricted Stock Units | 22,642 | 0.00 | — | 22,642 | — | ↗ |
| 2021-12-22 | Silverman Joshua | Director | A-Award | A | Restricted Stock Units | 25,156 | 0.00 | — | 25,156 | — | ↗ |
| 2021-12-22 | SHULMAN JOHN D | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 145,773 | 3.43 | 500.0K | 5,703,544 | — | ↗ |
| 2021-12-22 | Bradley Greg | Director | A-Award | A | Restricted Stock Units | 22,642 | 0.00 | — | 22,642 | — | ↗ |
| 2021-12-22 | Bernstein Bruce | Director | A-Award | A | Restricted Stock Units | 22,642 | 0.00 | — | 22,642 | — | ↗ |
| 2021-11-29 | SHULMAN JOHN D | Director / 10% Owner | P-Purchase | A | Warrant | 375,000 | 3.50 | 1.31M | 375,000 | — | ↗ |
| 2021-10-18 | SHULMAN JOHN D | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,661,807 | 1.72 | 2.85M | 5,057,771 | — | ↗ |
| 2021-05-11 | Gesek Andrew | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 3.21 | 240.8K | 75,000 | — | ↗ |
| 2021-05-11 | Arnold Mitchell | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.21 | 160.5K | 50,000 | — | ↗ |
| 2021-04-08 | WALKER WAYNE REMELL | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.18 | 159.0K | 50,000 | — | ↗ |
| 2021-04-08 | Silverman Joshua | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.18 | 159.0K | 50,000 | — | ↗ |
| 2021-04-08 | SHULMAN JOHN D | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 50,000 | 3.18 | 159.0K | 50,000 | — | ↗ |
| 2021-04-08 | Bradley Greg | Director | A-Award | A | Stock Options (right to buy) | 50,000 | 3.18 | 159.0K | 50,000 | — | ↗ |
| 2021-04-08 | Bernstein Bruce | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.18 | 159.0K | 50,000 | — | ↗ |
| 2021-03-23 | Metuchen Therapeutics, LLC | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-19 | Boctor Fady | Officer | A-Award | A | Stock Options (right to buy) | 215,669 | 3.74 | 806.6K | 215,669 | — | ↗ |
| 2020-12-01 | WALKER WAYNE REMELL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-01 | Silverman Joshua | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-01 | SHULMAN JOHN D | Director / 10% Owner | A-Award | A | Common Stock, par value $0.0001 per share | 3,382,416 | 0.00 | — | 3,382,416 | — | ↗ |
| 2020-12-01 | Lavan Keith | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-01 | Gesek Andrew | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-01 | Bradley Greg | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-01 | Boctor Fady | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-01 | Bernstein Bruce | Director | — | D | Employee Stock Option (right to buy) | 2,000 | 44.56 | 89.1K | 0 | — | ↗ |
| 2020-01-19 | Arnold Mitchell | Officer | — | I | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 390 | — | ↗ |
Executive team
Top executives
Shares Outstanding
31.16M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Fady Boctor President and Chief Commercial Officer | 350.0K | 280.0K | 70.0K | 123.1K | — | 52.0K | 875.1K | 22.07% | ↗ |
| 2 | 2023 | Mitchell Arnold Vice President of Finance and Chief Accounting Officer | 288.8K | 115.5K | — | 22.6K | — | 61.4K | 488.3K | 4.62% | ↗ |
| 3 | 2022 | Fady Boctor President and Chief Commercial Officer | 350.0K | 280.0K | — | — | — | 52.2K | 682.2K | 0.00% | ↗ |
| 4 | 2022 | Mitchell Arnold Vice President of Finance and Chief Accounting Officer | 288.8K | 60.0K | — | — | — | 58.3K | 407.0K | 0.00% | ↗ |
| 5 | 2022 | Andrew Gesek Former President, Timm Medical | 128.8K | — | — | — | — | 7.0K | 135.8K | 0.00% | ↗ |
| 6 | 2021 | Fady Boctor President and Chief Commercial Officer | 350.0K | 125.0K | — | 658.3K | — | 44.5K | 1.18M | 55.89% | ↗ |
| 7 | 2021 | Andrew Gesek Former President, Timm Medical | 300.0K | — | — | 197.5K | — | 47.9K | 545.4K | 36.21% | ↗ |
| 8 | 2021 | Mitchell Arnold Vice President of Finance and Chief Accounting Officer | 262.5K | 50.0K | — | 131.7K | — | 53.4K | 497.6K | 26.46% | ↗ |
| 9 | 2020 | Fady Boctor President and Chief Commercial Officer | 275.7K | 125.0K | — | — | — | 67.1K | 467.9K | 0.00% | ↗ |
| 10 | 2020 | Keith Lavan Chief Financial Officer | 316.9K | 50.0K | — | — | — | 95.6K | 462.5K | 0.00% | ↗ |
| 11 | 2020 | Andrew Gesek President, TIMM Medical | 270.0K | 75.0K | — | — | — | 62.4K | 407.4K | 0.00% | ↗ |
| 12 | 2020 | Andrew Gesek Former President, Timm Medical | 270.0K | 75.0K | — | — | — | 62.4K | 407.4K | 0.00% | ↗ |
| 13 | 2020 | Mitchell Arnold Vice President of Finance and Chief Accounting Officer | 236.3K | 50.0K | — | — | — | 68.4K | 354.6K | 0.00% | ↗ |
| 14 | 2020 | Greg Ford Chief Executive Officer | 186.6K | — | — | — | — | 66.1K | 252.7K | 0.00% | ↗ |
| 15 | 2019 | Andrew Gesek President, TIMM Medical | 300.0K | — | — | — | 234.7K | 70.3K | 604.9K | 0.00% | ↗ |
| 16 | 2019 | Greg Ford Chief Executive Officer | 367.7K | — | — | — | — | 82.7K | 450.4K | 0.00% | ↗ |
| 17 | 2019 | Keith Lavan Chief Financial Officer | 335.3K | — | — | — | — | 78.0K | 413.3K | 0.00% | ↗ |
| 18 | 2019 | Fady Boctor President and Chief Commercial Officer | 208.3K | 50.0K | — | — | — | 81.4K | 339.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joshua N. Silverman | Executive Chairman of the Board | 521.3K | male |
| Fady Boctor | President & Chief Commercial Officer | 406.3K | male |
| Mitchell S. Arnold | Vice President of Finance & Chief Accounting Officer | 303.5K | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PTPI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
